Ulcerative Colitis Market – Growth, Segment, Regional Analysis, and Forecasts(2023 to 2029)

Ulcerative Colitis Market has valued at US$ 6.91 Bn. in 2022. The Global Ulcerative Colitis Market size is estimated to grow at a CAGR of 5.7 % over the forecast period.

Ulcerative Colitis Market Overview:

Ulcerative Colitis is the most common form of inflammatory bowel disease that affects several people. It causes ulcers and inflammation in the digestive tract. The innermost lining of the large intestine and the rectum are affected by ulcerative colitis. Ulcerative colitis can strike anyone at any age, but it is more frequent in persons aged 15 to 30. Ulcerative colitis symptoms vary from person to person and may include diarrhea, passing blood in the stool, and immunological response in the abdomen. It is most common in Europe and North America but rare in most developing Asian countries. Males are more likely to develop UC, which varies from north to south region. The factors expected are disparities in ultraviolet light exposure, which results in insufficiency of Vitamin D near the Arctic countries. People who reside at lower latitudes have a higher risk of developing UC than those who live at higher latitudes.Ulcerative Colitis Market To know about the Research Methodology :- Request Free Sample Report The report segments the market based on Type, Molecule Type, Route of Administration, and End-User industry. North America is the dominant player in the fabrication service market. The report thoroughly analyzes market drivers, limitations, and opportunities. The report explores the different segments and data that have been provided by market participants and regions. This MMR report includes investor recommendations based on a thorough examination of the Cell Proliferation Kits market's contemporary competitive scenario.

Ulcerative Colitis Market Dynamics:

The rise in the incidence of inflammatory gastrointestinal illness, an increase in ulcerative colitis cases, and the development of medications for ulcerative colitis treatment by a large number of important companies are driving the ulcerative colitis market growth. According to a 2022 ulcerative survey conducted by Mark D. Basson, ulcerative colitis affected 1 million people in the United States. The high prevalence of ulcerative colitis is the driving force behind the growth of ulcerative colitis treatment. The rise in the burden of inflammatory bowel disease is expected to increase the demand and boost the ulcerative colitis market. The emergence of biosimilars is fueling the market growth. Biosimilars are expected to be cheaper than bio pharmacies and more accessible in developing countries. The expected patent expiration of some drugs is one of the factors responsible for the launch of new biosimilars. The growing participation of key players in the development of domain-related products is anticipated to drive this segment. The factors attributing to the growth are the introduction of novel therapies with a better clinical profile and patient-friendly RoA and increased penetration of targeted and advanced therapies. The market for ulcerative colitis treatment is also growing owing to the rising health care cost around the world and the increased efforts by governmental and non-governmental organizations to do biologics research. The harmful side effects of ulcerative colitis drugs and the lack of public awareness can hinder the market growth during the forecast period. The continued research and development to introduce new pharmaceuticals and the chance to develop generic drugs provide future growth opportunities for market vendors. The market growth is expected to be hampered by the strict government restrictions governing medicine approval.

Ulcerative Colitis Market Segment Analysis:

Based on the Type, the ulcerative colitis market is segmented into Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pan Colitis or Universal Colitis, and Fulminant Colitis. The ulcerative proctitis segment held the biggest market share of 57.23% in 2022. It is the earliest sign of ulcerative colitis. The market growth is boosted by the increased occurrence of ulcerative proctitis. Ulcerative Colitis Market Based on Molecule Type, the market is segmented into Small Molecules and Biologics. The small molecule segment has dominated the market in 2022 and is expected to continue during the forecast period because of the many important players supplying medications for ulcerative colitis treatment and advances in R&D activities. Due to the increase in inflammatory gastrointestinal disorders and increased use of ulcerative colitis medications, the biologics segment is anticipated to develop during the forecast period. Based on the Route of Administration, the market is segmented into Injectable and Oral. The oral segment held a significant market share of 65.56% in the year 2022 because of the development of new oral drugs to treat ulcerative colitis. Owing to the increased Research and Development activities in the pharmaceutical & medical device industry, there is a rise in the demand for drugs required for treatment has boosted the market growth. With the rising number of ulcerative colitis cases and the increase in the number of payers in the medical device sector developing novel medications, the injectable segment is expected to grow during the forecast period. Based on End-User, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Drug stores, and Others. The hospital pharmacy segment held the major market share and has valued at USD 3.30 billion in 2022. The growing number of ulcerative colitis patients increases the total number of hospitalizations resulting in the growth in the hospital pharmacy industry.

Regional Insights:

North America has dominated the largest market for ulcerative colitis drugs in 2022 with a market value of USD 3.16 Billion and is expected to dominate during the forecast period. The North American market is tremendously growing in the healthcare industry. The region has emerged has as a center for technical innovation and transformation. The Asia Pacific region is expected to witness significant growth at a CAGR of 6.5% through the forecast period. The rising consumer health awareness and increasing healthcare expenditure in this region are driving the market growth. The objective of the report is to present a comprehensive analysis of the global Ulcerative Colitis Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear, futuristic view of the industry to the decision-makers. The reports also help in understanding the Ulcerative Colitis Market dynamic, and structure by analyzing the market segments and projecting the Ulcerative Colitis Market size. Clear representation of competitive analysis of key players by Design, price, financial position, product portfolio, growth strategies, and regional presence in the Ulcerative Colitis Market make the report investor’s guide.

Ulcerative Colitis Market Scope: Inquiry Before Buying

Ulcerative Colitis Market
Report Coverage Details
Base Year: 2022 Forecast Period: 2023-2029
Historical Data: 2018 to 2022 Market Size in 2022: US$ 6.91 Bn.
Forecast Period 2023 to 2029 CAGR: 5.7% Market Size in 2029: US$ 10.20 Bn.
Segments Covered: by Type Ulcerative Proctitis Proctosigmoiditis Left-sided Colitis Pan Colitis or Universal Colitis Fulminant Colitis
by Molecule Type Small Molecules Biologics
by Route of Administration Injectable Oral
by End-User Hospital Pharmacies Retail Pharmacies Drug Store Others

Ulcerative Colitis Market by Region

Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) North America (United States, Canada and Mexico) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)

Key Players:

1. Ajinomoto Co. Inc 2. AstraZeneca PLC 3. Eli-Lilly 4. Index Pharmaceuticals Holdings AB 5. Johnson & Johnson 6. Pfizer Inc. 7. Sanofi S.A. 8. AbbVie Inc. 9. Merck & Co. Inc 10. Novartis AG 11. Bausch Health Companies Inc. 12. GlaxoSmithKline PLC 13. Bayer AG Frequently Asked Questions: 1. What is the market size of the Ulcerative Colitis Market in 2022? Ans. The market size Ulcerative Colitis market in 2022 was USD 6.91 Bn. 2. What are the different segments of the Ulcerative Colitis Market? Ans. The Ulcerative Colitis market is divided into Type, Molecule Type, Route of Administration and End-User. 3. Who are the key players in the market? Ans. Abbott Laboratories, Ajinomoto Co. Inc, AstraZeneca PLC, Eli-Lilly, and Index Pharmaceuticals Holdings AB is the major leading player. 4. What is the forecast period for this market? Ans. The Ulcerative Colitis market will be studied from 2023 to 2029. 5. Which region is expected to hold the highest market share? Ans. North America dominates the market share in the metal market.
1. Global Ulcerative Colitis Market Size: Research Methodology 2. Global Ulcerative Colitis Market Size: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Ulcerative Colitis Market Size 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Ulcerative Colitis Market Size: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • The Asia Pacific • The Middle East and Africa • Latin America 3.12. COVID-19 Impact 4. Global Ulcerative Colitis Market Size Segmentation 4.1. Global Ulcerative Colitis Market Size, by Type (2022-2029) • Ulcerative Proctitis • Proctosigmoiditis • Left-sided Colitis • Pan Colitis or Universal Colitis • Fulminant Colitis 4.2. Global Ulcerative Colitis Market Size, by Molecule Type (2022-2029) • Small Molecules • Biologics 4.3. Global Ulcerative Colitis Market Size, by Route of Administration (2022-2029) • Injectable • Oral 4.4. Global Ulcerative Colitis Market Size by End-User (2022-2029) • Hospital Pharmacies • Retail Pharmacies • Drug Store • Others 5. North America Ulcerative Colitis Market (2022-2029) 5.1. North America Ulcerative Colitis Market Size, by Type (2022-2029) • Ulcerative Proctitis • Proctosigmoiditis • Left-sided Colitis • Pan Colitis or Universal Colitis • Fulminant Colitis 5.2. North America Ulcerative Colitis Market Size, by Molecule Type (2022-2029) • Small Molecules • Biologics 5.3. North America Ulcerative Colitis Market Size, by Route of Administration (2022-2029) • Injectable • Oral 5.4. North America Ulcerative Colitis Market Size by End-User (2022-2029) • Hospital Pharmacies • Retail Pharmacies • Drug Store • Others 5.5. North America Ulcerative Colitis Market, by Country (2022-2029) • The United States • Canada • Mexico 6. European Ulcerative Colitis Market (2022-2029) 6.1. European Ulcerative Colitis Market, by Type (2022-2029) 6.2. European Ulcerative Colitis Market, by Molecule Type (2022-2029) 6.3. European Ulcerative Colitis Market, by Route of Administration (2022-2029) 6.4. European Ulcerative Colitis Market, by End-User (2022-2029) 6.5. European Ulcerative Colitis Market, by Country (2022-2029) • The UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Ulcerative Colitis Market (2022-2029) 7.1. Asia Pacific Ulcerative Colitis Market, by Type (2022-2029) 7.2. Asia Pacific Ulcerative Colitis Market, by Molecule Type (2022-2029) 7.3. Asia Pacific Ulcerative Colitis Market, by Route of Administration (2022-2029) 7.4. Asia Pacific Ulcerative Colitis Market, by End-User (2022-2029) 7.5. Asia Pacific Ulcerative Colitis Market, by Country (2022-2029) • China • India • Japan • South Korea • Australia • ASIAN • Rest Of APAC 8. Middle East and Africa Ulcerative Colitis Market (2022-2029) 8.1. Middle East and Africa Ulcerative Colitis Market, by Type (2022-2029) 8.2. Middle East and Africa Ulcerative Colitis Market, by Molecule Type (2022-2029) 8.3. Middle East and Africa Ulcerative Colitis Market, by Route of Administration (2022-2029) 8.4. Middle East and Africa Ulcerative Colitis Market by End-User (2022-2029) 8.5. Middle East and Africa Ulcerative Colitis Market, by Country (2022-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. Latin America Ulcerative Colitis Market (2022-2029) 9.1. Latin America Ulcerative Colitis Market, by Type (2022-2029) 9.2. Latin America Ulcerative Colitis Market, by Molecule Type (2022-2029) 9.3. Latin America Ulcerative Colitis Market, by Route of Administration (2022-2029) 9.4. Latin America Ulcerative Colitis Market, by End-User (2022-2029) 9.5. Latin America Ulcerative Colitis Market, by Country (2022-2029) • Brazil • Argentina • Rest Of Latin America 10. Company Profile: Key players 10.1. Ajinomoto Co. Inc 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Development 10.2. AstraZeneca PLC 10.3. Eli-Lilly 10.4. Index Pharmaceuticals Holdings AB 10.5. Johnson & Johnson 10.6. Pfizer Inc. 10.7. Sanofi S.A. 10.8. AbbVie Inc. 10.9. Merck & Co. Inc 10.10. Novartis AG 10.11. Bausch Health Companies Inc. 10.12. GlaxoSmithKlinethkline PLC 10.13. Bayer AG

About This Report

Report ID 148434
Category Healthcare
Published Date July 2023
Updated Date
  • INQUIRE BEFORE BUYING